
CNTB Stock Forecast & Price Target
CNTB Analyst Ratings
Bulls say
Connect Biopharma Holdings Ltd. is positioned favorably due to its innovative approach in developing rademikibart, which has demonstrated one of the largest reported improvements in FEV1 among biologics in its Phase 2 asthma study, indicating strong efficacy particularly in acute settings. The capability of rademikibart to target both acute and chronic conditions enhances its market potential, which could significantly increase the long-term value of Connect Biopharma’s shares. Furthermore, projected clinical data by the end of 2025 may further underscore the therapeutic advantages of rademikibart, contributing to an optimistic outlook for the company’s growth trajectory.
Bears say
Connect Biopharma Holdings Ltd faces significant challenges that contribute to a negative outlook on its stock. Increased competition in the market may hinder the company's ability to capture market share, leading to potential sales that fall short of expectations. Additionally, issues relating to patent disputes, challenging reimbursement landscapes, and the risk of unfavorable outcomes in ongoing clinical trials could further jeopardize the company's competitive position and revenue potential.
This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.
CNTB Analyst Forecast & Price Prediction
Start investing in CNTB
Order type
Buy in
Order amount
Est. shares
0 shares